* Bioatla Inc BCAB.OQ BCAB.O is expected to show no
change in
quarterly revenue when it reports results on August 8 for the
period ending June 30 2024
*
* LSEG's mean analyst estimate for Bioatla Inc is for a
loss
of 44 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bioatla Inc
is
$10.00, above its last closing price of $1.44.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.54 -0.54 -0.48 Beat 11.4
Dec. 31 2024 -0.88 -0.79 -0.56 Beat 29.3
Sep. 30 2023 -0.82 -0.80 -0.70 Beat 12.5
Jun. 30 2023 -0.63 -0.64 -0.75 Missed -17.2
Mar. -0.63 -0.63 -0.58 Beat 7.6
31 2023
Dec. 31 2022 -0.62 -0.70 -0.63 Beat 9.7
Sep. 30 2022 -0.80 -0.80 -0.69 Beat 13.8
Jun. 30 2022 -0.70 -0.69 -0.77 Missed -12.3
This summary was machine generated August 7 at 02:06 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)